RELATIONSHIP BETWEEN SERUM CONCENTRATION AND DOSE OF VALPROIC ACID DURING MONOTHERAPY IN ADULT OUTPATIENTS

被引:13
作者
TISDALE, JE
TSUYUKI, RT
OLES, KS
PENRY, JK
机构
[1] HENRY FORD HOSP,DEPT PHARM SERV,DETROIT,MI 48202
[2] UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1W5,BC,CANADA
[3] ROYAL COLUMBIAN HOSP,NEW WESTMINSTER,BC,CANADA
[4] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROL,WINSTON SALEM,NC 27103
关键词
VALPROIC ACID; SERUM CONCENTRATION; DOSE RATIOS; MONOTHERAPY; ADULTS;
D O I
10.1097/00007691-199210000-00013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The relationship between serum concentration and dose of valproic acid (VPA) is reported to be variable and inconsistent. However, studies evaluating this relationship have included individuals of varying ages and patients receiving potentially interacting medications. In this study, the relationship between VPA serum concentration and dose was evaluated in a homogeneous patient population. Medical records of 60 adult outpatients with epilepsy receiving VPA monotherapy were examined retrospectively for VPA dose (milligrams per kilogram) and corresponding serum VPA concentrations. A significant linear correlation was found in the relationship between VPA dose and serum concentration among all patients (r = 0.63; p < 0.01). However, considerable interindividual variability in this ratio was demonstrated [coefficient of variation (CV) = 28.99%], and the ratio was significantly dependent on VPA dose. In three selected individual patients, a significant linear correlation was also demonstrated in the VPA serum concentration:dose relationship over time (r = 0.91, 0.94, 0.96; p < 0.05 for all three patients) with substantially less variability (CV = 10.2-14.6%) and without significant dose dependency, suggesting that this parameter may be useful for guiding VPA dosage adjustment and monitoring patient compliance. Further study is required to evaluate the utility of the serum concentration:dose ratio in monitoring VPA therapy.
引用
收藏
页码:416 / 423
页数:8
相关论文
共 22 条
[1]  
BARUZZI A, 1977, INT J CLIN PHARM BI, V15, P403
[2]  
Bourgeois B F, 1988, Am J Med, V84, P29, DOI 10.1016/0002-9343(88)90054-X
[3]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492
[4]  
BRUNI J, 1978, CLIN PHARMACOL THER, V24, P324
[5]   VALPROATE MONOTHERAPY IN THE MANAGEMENT OF GENERALIZED AND PARTIAL SEIZURES [J].
CHADWICK, DW .
EPILEPSIA, 1987, 28 :S12-S17
[6]   PHARMACOKINETICS OF VALPROIC ACID IN CHILDREN .1. MULTIPLE ANTI-EPILEPTIC DRUG-THERAPY [J].
CLOYD, JC ;
KRIEL, RL ;
FISCHER, JH ;
SAWCHUK, RJ ;
EGGERTH, RM .
NEUROLOGY, 1983, 33 (02) :185-191
[7]  
DANIEL WW, 1987, BIOSTATISTICS F ANAL
[8]   PHARMACOLOGY OF VALPROIC ACID IN CHILDREN WITH SEVERE EPILEPSY - CLEARANCE AND HEPATOTOXICITY [J].
DODSON, WE ;
TASCH, V .
NEUROLOGY, 1981, 31 (08) :1047-1050
[9]  
GRAML, 1980, ANTIEPILEPTIC THERAP, P247
[10]   1ST-DOSE AND STEADY-STATE PHARMACOKINETICS OF VALPROIC ACID IN CHILDREN WITH SEIZURES [J].
HALL, K ;
OTTEN, N ;
IRVINEMEEK, J ;
LEROUX, M ;
BUDNICK, D ;
VERMA, M ;
SESHIA, SS .
CLINICAL PHARMACOKINETICS, 1983, 8 (05) :447-455